Exploring the HYDRAtion method for loading siRNA on liposomes : the interplay between stability and biological activity in human undiluted ascites fluid by Dakwar, George et al.
 
 
biblio.ugent.be 
 
The UGent Institutional Repository is the electronic archiving and dissemination platform for 
all UGent research publications. Ghent University has implemented a mandate stipulating 
that all academic publications of UGent researchers should be deposited and archived in this 
repository. Except for items where current copyright restrictions apply, these papers are 
available in Open Access. 
 
This item is the archived peer‐reviewed author‐version of: Exploring the HYDRAtion method 
for laoding siRNA on liposomes: the interplay between stability and biological activity in 
human undiluted ascites fluid     
Authors: Dakwar G., Braeckmans K., Ceelen W., De Smedt S.C., Remaut K.             
In: Drug Delivery and Translational Research 2017, 7(2): 241‐251 
 
To refer to or to cite this work, please use the citation to the published version: 
Dakwar G., Braeckmans K., Ceelen W., De Smedt S.C., Remaut K. (2017) 
Exploring the HYDRAtion method for laoding siRNA on liposomes: the interplay between 
stability and biological activity in human undiluted ascites fluid     
Drug Delivery and Translational Research 7(2): 241‐251 
DOI: 10.1007/s13346‐016‐0329‐4  
 
 
 
 
 
 
 
  
 
1 
 
Exploring the HYDRAtion method for loading siRNA on liposomes: the interplay 
between stability and biological activity in human undiluted ascites fluid 
George R. Dakwar1, Kevin Braeckmans1,2, Wim Ceelen3, Stefaan C. De Smedt1*, Katrien 
Remaut1** 
 
1 Ghent Research Group on Nanomedicines, Laboratory for General Biochemistry and Physical 
Pharmacy, Faculty of Pharmacy, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, 
Belgium 
2 Centre for Nano- and Biophotonics, Ghent University, 9000 Ghent, Belgium 
3 Department of Surgery, Ghent University Hospital, De Pintelaan 185, B9000 Ghent, Belgium 
Author information 
* Corresponding author. Tel.: +32 9 2648076; fax: +32 9 2648189. 
** Corresponding author. Tel.: +32 9 2648078; fax: +32 9 2648189 
E-mail addresses: stefaan.desmedt@ugent.be (S.C. De Smedt), Katrien.Remaut@ugent.be (K. 
Remaut) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Abstract 
Delivery of small interfering RNA (siRNA) is recently gaining tremendous attention for the 
treatment of ovarian cancer. The present study investigated the potential of different liposomal 
formulations composed of (2, 3-Dioleoyloxy-propyl)-trimethylammonium (DOTAP) and 1, 2-
Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) encapsulating siRNA (hydration 
method) for their ability to knockdown luciferase (Luc) activity in human ovarian cancer 
SKOV-3 cells. Fluorescence Single Particle Tracking (fSPT) and fluorescence correlation 
spectroscopy (FCS) in human undiluted ascites fluid obtained from a peritoneal carcinomatosis 
patient revealed that cationic hydra-lipoplexes (HYDRA-LPXs) and HYDRA-LPXs decorated 
with stable DSPE-PEG (DSPE HYDRA-LPXs) showed high stability during at least 24 hours. 
HYDRA-LPXs decorated with sheddable C8 and C16 PEG-Ceramides (Cer HYDRA-LPXs) 
resulted in rapid and premature release of siRNA already in the first hours. Despite their role in 
preventing aggregation in vivo, liposomes decorated with stable PEG residues resulted in a poor 
transfection compared to the ones decorated with sheddable PEG residues in reduced serum 
conditions. Yet, the transfection efficiency of both Cer HYDRA-LPXs significantly decreased 
following 1 hour of incubation in ascites fluid due to a drastic drop in the cellular uptake, while 
DSPE HYDRA-LPXs are still taken up by cells, but too stable to induce efficient gene 
silencing.  
Keywords: siRNA delivery, siRNA encapsulation, peritoneal metastasis, sheddable PEG, 
ascites  
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Introduction 
Small interfering RNA (siRNA) therapeutics hold great potential for the treatment of 
different diseases, such as neurodegenerative pathologies, genetic and metabolic disorders and 
cancer [1, 2]. To ensure their therapeutic activity, siRNA-based medicines should be delivered 
into the cytoplasm of the target cell where the natural RNAi machinery could be engaged. 
Towards this goal, complexation or encapsulation of siRNA within nano-sized particles is being 
utilized to protect the siRNA from blood nucleases and other extracellular components with the 
aim to increase the fraction that enters into cells following administration. Apart from protection 
of the siRNA against nucleases , these nano-carriers should also (i)  be resistant to the formation 
of large aggregates while circulating in the extracellular biofluids, (ii) prevent premature release 
of the siRNA before reaching the target cell [3], and (iii)  (sufficiently) interact extracellularly 
with the plasma membrane and intracelluarly with the endosomal membrane, an interaction 
which is essential for therapeutic activity of siRNA [3, 4]. 
Over the last decade, both polymeric and lipid nanoparticles (LNPs) were employed for 
siRNA delivery [2, 5]. Due to the negative charge of the siRNA, cationic lipid-based and 
polymeric NPs are widely used to obtain spontaneous electrostatic interactions and protect the 
siRNA from degradation [6-8]. The most important difference between the lipid-based and 
polymeric vehicles is that the majority of the cationic polymers do not contain a hydrophobic 
tail, and thus are completely soluble in water. Also, cationic polymers can be synthesized in 
different molecular weights and shapes (linear versus branched) and can be more easily tuned 
with functional groups, to influence, for example, the intracellular trafficking of the vehicles 
and their biological activity [8, 9]. Generally speaking, LNPs contain a lipid bilayer-disrupting 
lipids that are activated by low endosomal pH, whereas polymers are very easy to modify and 
control their structure in a way that they become positively charged in acidic endosomes in 
order to enhance endosomal escape of siRNA [10].     
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 Lipid nanoparticles (LNPs) have been extensively investigated as candidates for siRNA 
delivery in cancer therapy [11]. Currently, LNPs represent the most promising platform for 
systemic delivery of siRNAs, with lipid-based formulations in clinical trials for the treatment 
of different diseases [2, 5]. Despite major advances with LNPs for siRNA delivery, the main 
challenge remains their colloidal stability within the fluids of the body. In this context, grafting 
LNPs with polyethylene glycol (PEG) is the most common strategy to prevent aggregation and 
prolong their half-life in the circulation [12]. PEGylation, however, has been associated with 
poor biological activity of siRNA [12]. It is speculated that PEG chains significantly decrease 
the uptake of LNPs by cells and disrupt their interaction with the endosomal membrane [4, 13]. 
For instance, increasing the PEGylation of siRNA-lipoplexes (siRNA-LPXs) from 2 to 5 mol% 
dramatically diminished the siRNA gene silencing in vivo [14]. Furthermore, it has been 
postulated that multiple administration of stabilized PEGylated lipid particles (SPLP), induced 
a strong immune response against PEG, resulting in accelerated blood clearance [15-17]. Worth 
mentioning also is that PEG residues interfere with the electrostatic interactions between 
negatively charged siRNA and positively charged lipids resulting in a low 
complexation/encapsulation efficiency. Also, we observed that PEGylation leads to the rapid 
premature release of the siRNA from the surface of the liposomes in different biological fluids 
[18-20].  
Therefore, when tailoring LNPs for in vivo siRNA delivery, a delicate balance between 
avoiding (i) aggregation, (ii) premature release, (iii) immune responses and realizing efficient 
intracellular release of siRNA in the cytoplasm of cells should be installed to overcome PEG-
associated problems. In this respect, an interesting approach could be the use of ‘exchangeable’ 
PEG-derivatized lipids, also called “sheddable PEG”, which diffuse out of LPXs upon contact 
with biological membranes, depending on the length of the acyl) chain of the lipid anchor. 
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Among the most used sheddable PEG-lipids are ceramides (Cer-PEG) and diacylglycerols 
(PEG-S-DAGs) [21, 22]. 
Ovarian cancer leads to more than 140,000 deaths annually in women around the world 
[23]. In the majority of the cases, ovarian cancer often migrates to the peritoneal cavity forming 
fatal peritoneal carcinomatosis. Interestingly, intraperitoneal (i.p.) administration of different 
drugs has recently shown some advantages to treat peritoneal tumors when compared to 
intravenous administration, mainly due to high concentrations of drug at the tumor site 
following i.p. administration [24-26]. Also, the delivery of siRNA to ovarian cancer cells using 
different nano- sized carriers is recently gaining increasing attention in cancer therapy [27-30]. 
It has been reported that the co-delivery of chemotherapeutic agents with siRNA is an efficient 
strategy to enhance tumor killing effect and overcome resistance of cancer cells when compared 
to delivery systems carrying either siRNA or chemotherapeutics alone [31-33]. First of all, 
siRNAs can specifically silence cancer associated genes, causing less side effects in non-cancer 
cells. Moreover, siRNA is not limited to target receptors that are expressed on the surface of 
cancer cells, but can also silence genes associated with intracellular targets [34]. 
 
 In this study, we investigate the suitability of different liposomes (cationic, PEGylated 
and grafted with diffusible Cer-PEG) composed of DOTAP and DOPE (as lipids) encapsulating 
siRNA within the aqueous core (prepared by the hydration method) [18, 35] to knockdown 
luciferase in the human ovarian cancer cell line SKOV-3. Initially we employ advanced 
fluorescence microscopy techniques, such as fluorescence correlation spectroscopy (FCS) and 
fluorescence single particle tracking (fSPT) [36, 37] to follow the release and aggregation of 
the LPXs in ascites fluid obtained from a peritoneal carcinomatosis patient. Additionally, we 
test the uptake, toxicity and silencing efficiency of all the formulations. We hypothesized that 
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liposomes encapsulating siRNA and decorated with diffusible Cer-PEG may be an attractive 
strategy to target tumors confined within the peritoneal cavity following i.p. adminstration, as 
they represent a fine balance between PEGylation and de-PEGylation [38].   
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Materials and Methods  
Materials 
(2,3-Dioleoyloxy-propyl)-trimethylammonium-chloride (DOTAP) and 1,2-Dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE) were purchased from Corden Pharma LLC (Liestal, 
Switzerland). 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] 
(DSPE-PEG), N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene-glycol)2000]} 
(C16 mPEG 2000 Ceramide), N-octanoyl-sphingosine-1-{succinyl[methoxy(polyethylene 
glycol)2000]} (C8 mPEG 2000 Ceramide) were purchased from Avanti Polar Lipids  
(Alabaster, AL, USA). Chloroform, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and 
sodium chloride (NaCl) were purchased from Sigma Aldrich (Bornem, Belgium).  
Penicillin-Streptomycin (5000 U/ml), L-Glutamine (200 mM), 0.25% Trypsin-EDTA (1X) 
Phenol Red, McCoy's 5A (Modified), Opti-MEM® and 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine perchlorate (DID) (λex= 644 nm, λem= 665 nm) were 
purchased from Invitrogen (Merelbeke, Belgium). Luciferase Assay Substrate was purchased 
Promega (Madison, WI, USA). Fetal Bovine Serum (FBS) was purchased from HyClone® 
Thermo Scientific (Cramlington, UK). Passive Lysis Buffer and Luciferase Assay Kit were 
purchased from (Promega, Leiden, Netherlands).  
Preparation and characterization of the HYDRA LPXs 
 
Liposomes corresponding to 5 mM of DOTAP and 5 mM of DOPE lipids were prepared by 
mixing the appropriate amount of each lipid in a round bottomed flask before evaporation.  
PEGylated liposomes were prepared by adding the desired amounts of DSPE-PEG, or C8 Cer-
PEG or C16 Cer-PEG dissolved in chloroform (corresponding to 5 mol% the total lipids) to 
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the lipids before evaporation. A lipid film was formed by rotary evaporation of the chloroform 
at 40°C.  
To obtain the so named ‘HYDRA lipoplexes’, the dried lipid film was hydrated with a siRNA 
solution in HEPES buffer (20 mM, pH 7.4) resulting in LPXs with a charge ratio of ± 8. Finally, 
the obtained solution was sonicated using a probe sonicator (Branson Ultrasonics Digital 
Sonifier®,Danbury,USA).We showed previously that this method results in the encapsulation 
of 50% of the complexed siRNA inside the liposomes and 50% bound to the outer surface of 
the liposomes [35]. The average size and zeta potential of all formulations were measured 
using Zetasizer Nano-ZS (Malvern, Worcestershire, UK).   
Fluorescence single particle tracking (fSPT) 
Fluorescence Single particle tracking (fSPT) is a fluorescence microscopy technique which is 
used to characterize the diffusion of nanoparticles. Briefly, fSPT makes use a fast CCD camera 
and wide-field laser illumination to obtain movies of single, fluorescently labeled particles in 
biological media. The movies are then analyzed by using in-house image processing software 
[36], where the motion trajectories and subsequently the diffusion coefficient of each individual 
particle is calculated. Based on the trajectories of all the particles, it is possible to make a 
distribution of diffusion coefficients, which is then converted into size distribution using the 
Stokes-Einstein equation given the viscosity of the biofluid at which the experiment was 
performed is known. Finally, the distribution is refined by the maximal entropy method [36]. 
We showed previously that fSPT is ideally suited to characterize the size (and thus the extent 
of aggregation) of nanoparticles in biological fluids like human serum, ascites fluid, human 
plasma, and blood [3, 20, 36]. The main advantage of fSPT over the widely used sizing 
techniques such as Dynamic Light Scattering (DLS), is the ability to perform sizing 
measurements in undiluted biological fluids, without the influence of the proteins present in 
these fluids [3].  
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fSPT measurements were performed on the HYDRA-LPXs (Cationic, 5% DSPE-PEG, 5% C8 
Cer-PEG, 5% C16 Cer-PEG) labeled with the lipophilic dye DID, that labels the lipid bilayer 
of the liposomes). LPXs were dispersed in biofluids as follows. First, formulations were diluted 
400 times in HEPES buffer. Then 5 µl was added to 45 µl of biofluid (~90 vol% of ascites 
fluid), and incubated for 1, 2 and 3 h at 37°C in a 96-well plate (Greiner bio-one, Frickenhausen, 
Germany). fSPT-videos of the different formulations in the biofluids were recorded with the 
NIS Elements software (Nikon) driving the EMCCD camera (Cascade II:512, Roper Scientific, 
AZ, USA) and a TE2000 inverted microscope equipped with a 100_ NA1.4 oil immersion lens 
(Nikon) as previously described [3, 20] using the following values of viscosity at room 
temperature: 1.39 cP for human ascites fluid and 0.94 for HEPES buffer [3]. Human ascites 
fluid was obtained from a patient diagnosed with peritoneal carcinomatosis at the Medical 
Oncology Department of Ghent University Hospital (approved by the Ethics Committee of the 
Ghent University Hospital (no. 2013/589)).  
Videos were recorded at room temperature (22.5 °C) with the NIS Elements software (Nikon) 
driving the EMCCD camera (Cascade II: 512, Roper Scientific, AZ, USA) and a TE2000 
inverted microscope equipped with a 100_ NA1.4 oil immersion lens (Nikon). 
Fluorescence Correlation Spectroscopy on HYDRA LPXs 
FCS is a microscopy-based technique that monitors the fluorescence intensity fluctuations of 
molecules diffusing in and out of the focal volume of a confocal microscope [3]. When free 
fluorescently labeled siRNA molecules pass through the focal volume, a fluorescence baseline 
with an intensity that corresponds to the concentration of the free labeled siRNA molecules is 
obtained. When the siRNA is complexed/encapsulated within a carrier, the concentration of 
free siRNA drops and subsequently, a drop in the baseline intensity of the fluorescence signal 
occurs, accompanied with fluorescence fluctuations (i.e. peaks) each time a complex passes the 
focal volume. Release of siRNA, on its turn, results in an increase in the fluorescence baseline. 
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An important advantage of FCS is the low volume of samples needed to perform the 
experiments (~50 µl).  Our group showed before that FCS is ideally suited to measure the 
amount of siRNA that is released/associated from/with nano-sized carriers in various types of 
biofluids [3,4,15]. FCS measurements were carried-out on HYDRA-LPXs containing 30% Cy-
5 siRNA and 70% non-labeled siRNA, with a charge ratio of ± 8. 5 µl of LPXs were diluted to 
a final volume of 50 µl in respectively HEPES buffer or ascites fluid (~ 90 vol%) and FCS 
measurements were done (i) immediately after diluting the LPXs (in HEPES or ascites fluid), 
(ii) 1 h and (iii) 24 h after incubation with the biofluids at 37°C. FCS measurements were 
performed on a C1si laser scanning confocal microscope (Nikon, Japan), equipped with a time-
correlated single photon counting (TCSPC) data acquisition module (Picoquant, Berlin, 
Germany). The laser beam was held stationary and focused through a water immersion 
objective lens (Plan Apo 60, NA 1.2, collar rim correction, Nikon, Japan) at ~ 50 µm above the 
bottom of the glass-bottom 96-well plate (Grainer Bioone, Frickenhausen, Germany), which 
contained the fluorescent LPXs. The 633 nm laser beam was used to record fluorescence 
intensity fluctuations using SymPhoTime (Picoquant, Berlin, Germany).  
Cell culture 
The human ovarian cancer cell line SKOV-3 which stably expresses firefly luciferase was used 
for in vitro experiments. Cells were cultured in McCoy's 5A medium supplemented with FBS, 
Penicillin-Streptomycin and L-Glutamine. Cells were cultured until 80% to 90% confluency 
and detached from tissue culture dishes with 0.25% trypsin. Cells were maintained in an 
incubator at 37°C in a humidified atmosphere with 5% CO2.   
Cell viability assay 
The MTT assay was used as a measure of cell viability following incubation of the studied 
formulations with a final negative control siRNA concentration of 10, 15 and 20 nM. SKOV-3 
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cells were cultured on 24-well tissue culture plates (35,000 cells per well). On the next day, 
cells were incubated for 4 h with 500 µl Opti-MEM® containing the LPXs of interest or 30% 
of ethanol as positive control. Then, cells were washed and incubated with McCoy's 5A medium 
for an additional 24 h. Thereafter, 100 µl of MTT stock solution (5 mg/ml MTT in PBS) in 
McCoy's 5A was added to each well and incubated for 3 h. After aspirating the medium, 500 
µl of DMSO was added to each well in order to dissolve the formazan crystals. The plates were 
covered with aluminum foil, placed on an orbital shaker for 10 min and the absorbance of the 
formed formazan crystals was determined at 590 nm with reference at 690 nm using a Wallac 
EnvisionTM multilabel reader (PerkinElmer, Zaventem, Belgium). Percentages of cell viability 
for each sample were calculated as follows: (absorbance of the sample/absorbance of the 
negative control) x 100%.   
 
 
Internalization of siRNA into SKOV-3 cells 
SKOV-3 cells were plated on 24-well plates (35,000 cells in each well) and allowed to grow in 
an incubator for 24 h. Cells were incubated with the formulations containing 10% Alexa Fluor-
488 siRNA at a final siRNA concentration of 15 nM for 4 h at 37°C. At the end of the 
incubation, cells were washed extensively with warm growth medium and PBS, then detached 
using trypsin and analyzed by FACS (FACSCalibur Flow Cytometer, BD Biosciences, USA). 
Uptake experiments were done with LPXs administered in Opti-MEM® or with LPXs which 
were first incubated for 1 h in human ascites fluid, as previously described [20]. Uptake 
experiments in the ascites fluid were performed by incubating 300 µl of each of the studied 
formulations with 700 µl of ascites fluid for 1 h at 37°C. Then, 300 µl of the mixture were 
added in triplicates to 700 µl of Opti-MEM® in each well of a 24 well-plate. After 4 h of 
incubation at 37°C, cells were washed, detached and analyzed as described above.  
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Transfection efficiency  
SKOV-3 cells were cultured on 24-well plates (35,000 cells/well) in 500 µl of medium 
containing 10% FBS 24 h prior to the transfection. Cells were incubated with HYDRA-LPXs 
at a final siRNA concentration of 15 nM respectively in Opti-MEM®  or following 1 h of pre-
incubation in ascites fluid as previously explained [20]. After 4 h incubation, the transfection 
medium was replaced by culture medium and cells were returned to the incubator for 24 h. 
Then, cells were lysed with Passive Lysis Buffer and analyzed for firefly luciferase expression 
using the luciferase assay kit (Promega). The bioluminescence (Relative Light Units, RLU) was 
measured using a GloMax Luminometer (Promega). The percentage of luciferase 
downregulation was determined by the following equation:  
% transfection = 100 – (100 x RLUluc/RLUctrl), where RLUctrl is the mean for control siRNA 
and RLUluc is the mean for luciferase siRNA. Transfection experiments were performed in 
triplicates on three different days. For transfections in the ascites fluid, 300 µl of each HYDRA-
LPX (of each formulation) were incubated with 700 µl ascites fluid and incubated for 1 h at 
37°C. Thereafter, 300 µl of the mixture was added to 700 µl of Opti-MEM® in each well of a 
24 well-plate. Then, the medium was replaced with growth medium and cells were returned to 
the incubator for 24 h, as described above.  
  Statistical analysis 
Statistical analysis on the transfection data (Figure 5) was performed using GraphPad Prism 6. 
Data are presented as means ± SD. Statistically significant differences were calculated by using 
an analysis of variance (ANOVA) at a 0.05 significance level, followed by Sidak’s post-test. 
For each formulation, transfection experiments carried out in Opti-MEM® were compared to 
these in ascites fluid.  
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 Results  
Characterization of the studied LPXs 
Table 1 shows the size and zeta potential of the different used formulations. In the 
hydration method, formulations were prepared by hydrating the lipid film with siRNA directly. 
This results in liposomes in which the siRNA is also encapsulated inside the aqueous core of 
the resulting LPXs, as well as being complexed to the outer surface of the liposomal 
formulations. As depicted in table 1, all the studied formulations resulted in nano-sized 
vesicles, as determined by dynamic light scattering (DLS). When compared to empty 
liposomes, the size increased for all formulations when LPXs were formed, except for the 5% 
C16 Cer HYDRA-LPXs. 
As expected, both PEGylation and the addition of siRNA influenced the charge of the 
liposomes. Introducing PEG chains on the surface of the liposomes results in shielding of the 
positive charge from about 56 mV for the cationic liposomes to about 17-20 mV for the 
PEGylated ones. Encapsulation of siRNA resulted in a further decrease of the charge, except 
for the 5% C16 Cer HYDRA-LPXs.   
 
Aggregation of the formulations in undiluted ascites fluid 
In our previous study we have shown that DLS is not an ideal technique for 
characterizing aggregation of nanoparticles in biological fluids, simply due to scattering that 
results from e.g. the proteins in the biofluids [3]. fSPT has proven to be superior over DLS for 
this purpose [3, 36]. Figure 1a shows the size distributions of the HYDRA-LPXs as measured 
by fSPT. In agreement with the DLS outcomes in Table 1, HYDRA-LPXs have an average size 
around 100 nm when measured in HEPES buffer (Figure 1a, black curve). Following 1 h of 
incubation in ascites fluid, the size distribution is shifted to the right (red curve), with a peak 
diameter around 200 nm. Upon longer times in ascites fluids, aggregation of the HYDRA-LPXs 
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seemed somehow to continue, resulting in HYDRA-LPXs with a peak diameter of 300 nm 
(Figure 1a, blue curve). After 3 h of incubation, the size distributions did not further change, 
indicating the aggregation reached an equilibrium already after 2 h (Figure 1a, green curve).  
Next, we were interested if PEGylation would further inhibits the aggregation of HYDRA-
LPXs. Two types of PEGylation were tested, namely the incorporation of respectively stable, 
non-exchangeable DSPE-PEG chains, and exchangeable PEG-Ceramides. In the case of the 
DSPE-PEG HYDRA-LPXs (Figure 1b), initially a minor aggregation was observed following 
incubation in ascites fluid when compared to the distribution in HEPES buffer (~ 150 nm). 
Then, the PEGylated complexes remained stable, resulting in particles of about 250 nm in 
diameter. For the 5% C8 Cer HYDRA-LPXs, the size in HEPES buffer was around 100 nm 
(Figure 1c) and increased to 200 nm after 1 h of incubation in ascites fluid. Surprisingly, further 
incubation in ascites fluid for 2 and 3 h resulted again in smaller 5% C8 Cer HYDRA-LPXs of 
150 nm and less. The SPT data in Figure 1D for the C16 Cer HYDRA-LPXs exhibit a similar 
behavior to the C8 Cer HYDRA-LPXs, with an equilibrium reached after 1 h of incubation in 
ascites fluid, and a peak diameter of about ~250 nm. Taken together, all the formulations 
seemed sufficiently stable in the ascites fluid:  no micrometer-sized aggregates were observed 
and the size of all LPXs remained sufficiently small to allow endocytosis by cells.  
 
Release of siRNA from the formulations in undiluted ascites fluid 
As demonstrated previously, FCS is a suitable method to follow the release of siRNA 
from different types of formulations in undiluted biological fluids [3, 19, 20]. Figure 2 displays 
the complexation efficiency of the studied formulations. HYDRA-LPXs show a high 
complexation efficiency with about 80% of the siRNA complexed with the liposomes 
immediately after preparation in HEPES buffer (Figure 2, white bars) and during 24 h (grey 
and green bars). Following 1 h of incubation (Figure 2, blue bars), a burst release was observed 
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leading to about 40% complexed siRNA (60% of free siRNA). This release is highly likely 
ascribed to the siRNA which is bound on the surface of the liposomes and not actually 
encapsulated inside. No substantial further release was noted after 24 h of incubation in ascites 
fluid, demonstrating that eventually about 35% of the siRNA was encapsulated within the 
aqueous core of the liposomes (magenta bars). PEGylation clearly influenced the complexation 
efficiency and release profile of the studied formulations. For DSPE HYDRA-LPXs, only 50% 
of the siRNA is complexed immediately after preparation, suggesting that PEGylation lowers 
the siRNA complexation efficiency (white bars). This 50% of siRNA, however, can be retained 
in the DSPE HYDRA-LPXs for the complete 24 h incubation period and is therefore most likely 
encapsulated inside the liposomes (Figure 2, magenta bars). For the Cer HYDRA-LPXs, the 
effect of PEGylation was even more pronounced, with 75% and 85% of free siRNA (e.g. 
uncomplexed) as such in HEPES buffer for the 5% C8 Cer and 5% C16 Cer HYDRA-LPXs 
respectively. Following 24 h of incubation in ascites fluid, both Cer HYDRA-LPXs resulted in 
around 90% of free siRNA (Figure 2, magenta bars).  
 
Cytotoxicity of the studied formulations 
The toxicity of the formulations was assessed on SKOV-3 human ovarian cancer cells 
using a MTT assay. As can be seen in Figure 3, the formulations did not exhibit any severe 
decrease in the metabolic activity of the cells, with maximum 20% mortality for the highest 
siRNA concentrations of 20 nM. A decrease in the cell viability was observed with increasing 
siRNA concentrations. To stay within the non-toxic range of concentrations, we decided to 
perform uptake and transfection experiments with a final concentration of 15 nM.  
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Cellular Uptake and transfection efficiency of the formulations by SKOV-3 cells 
To evaluate the ability of the different formulations to knockdown the expression of a specific 
gene, SKOV-3 cells stably expressing luciferase were incubated with the formulations 
containing siRNA against luciferase (luc siRNA). To verify the knockdown specificity, luc 
siRNA formulations were compared to the same formulations loaded with a scrambled negative 
control siRNA.  
We have recently proven the importance of performing uptake experiments of formulations 
carrying siRNA in the relevant biofluid [20]. Uptake is a key feature in siRNA delivery, since 
naked siRNA cannot internalize into cells due to its negative charge and hydrophilicity. To test 
whether the formulations are capable of delivering siRNA into cells, we incubated SKOV-3 
cells with fluorescently labeled LPXs and followed their uptake with flow cytometry. The 
outcomes of the uptake experiments shown in Figure 4 indicate that all the formulations are 
internalized into SKOV-3 cells at 37°C when incubated in serum reduced media (i.e. Opti-
MEM®), represented by high percentage of positive cells (Figure 4, white bars). Following 1 h 
of incubation in ascites fluid (Figure 4, grey bars), however, all the formulations completely 
lose their ability to be taken up by cells, except for the DSPE-HYDRA LPXs where cellular 
uptake still occurs. 
 
Figure 5 depicts the transfection efficiency of the studied formulations in Opti-MEM® (white 
bars) and following 1 h of incubation in ascites fluid (grey bars). In Opti-MEM®, it can be seen 
that only DSPE HYDRA-LPXs resulted in a very poor transfection efficiency (37%). All other 
formulations demonstrated high and significant downregulation of 70% for the HYDRA-LPXs, 
73% for the 5% C8 Cer HYDRA-LPXs and 80% for the 5% C16 Cer HYDRA-LPXs. Following 
incubation in ascites fluid, however, all the formulations lost their ability to silence luciferase, 
when compared with the situation in Opti-MEM®. 
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Discussion  
Choice of the study  
The final goal of this study is to assess the suitability of liposomal-based formulations 
loaded with siRNA via the hydration method and possessing different surface modifications in 
undiluted ascites fluid obtained from a peritoneal carcinomatosis patient for siRNA delivery. 
As a follow up of our previous study [3] and towards enhancing the stability of LPXs and 
maximizing their biological activity, we focused on two main aspects: 1) the siRNA loading 
method and 2) the PEGylation strategy. On the level of loading, we used the hydration method 
[18, 35], while on the level of PEGylation we decided to evaluate the stable DSPE-PEG, 
diffusible C8 and C16 Cer-PEG. The different PEG-chains were chosen to understand whether 
Cer-PEGylation can still play a role in preventing aggregation in the extracellular IP fluid, while 
the diffusion of the PEG-chains out of the liposomal formulations upon interaction with 
biological membranes would enhance the cellular uptake and endosomal escape on the 
intracellular level.  In this context, Cer-PEG with shorter C8 acyl chain lipids (C8) seems to be 
best candidates for local intraperitoneal delivery, due to the rapid exchange rate of the Cer-PEG 
from the surface of the liposomes, compared to the longer acyl chains (C20) [39]. Additionally, 
C8 Cer-PEG were successfully exploited to deliver plasmid DNA for regional gene therapy 
[40].  
 
Influence of PEGylation on encapsulation efficiency  
It is of interest to point out the differences between the hydration technique used in this 
study and the widely used complexation technique. With the conventional complexation 
technique, liposomes are prepared by hydrating the lipid film with a buffer solution. Then, 
LPXs are prepared by the simple mixing of siRNA and the preformed liposomes, taking 
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advantage of the electrostatic interactions between the negatively charged siRNA and the 
cationic liposomes. In this case the siRNA binds on the surface of the liposomes, and is not 
encapsulated into the aqueous core. We have previously demonstrated, however, that the 
surface bound siRNA in this classic complexation protocol is easily displaced when the 
liposomes are dispersed in biofluids such as human serum or ascites fluid, especially when 
PEGylated liposomes are used [3].  
We hypothesized that when using the hydration protocol [35], which ensures an even 
distribution of the negatively charged siRNA over the inner and outer core of a cationic lipid, 
the premature release of siRNA in the ascites fluid could be overcome [35]. Indeed, only the 
surface bound siRNA is expected to be released from the LPXs in the biofluids, while the 
siRNA encapsulated in the aqueous core is protected from premature release. Figure 2 
demonstrated that this hypothesis was valid to some extent. We have previously shown that 5% 
DSPE-PEG LPXs prepared with the classic complexation method, release the majority of the 
complexed siRNA immediately after incubation with ascites fluid [3]. For DSPE HYDRA-
LPXs, however, 50% of the siRNA is still encapsulated within the liposomes following 24 h of 
incubation in ascites fluid (Figure 2). This agrees with our assumption that with the hydration 
method, the siRNA within the aqueous core of the liposomes is protected from the external 
environment, and thus the negatively charged proteins (mainly albumin) which compete for 
binding to the liposomes. Also the non-PEGylated HYDRA-LPXs retain about 35-40% of the 
complexed siRNA within the aqueous core after 24 h of incubation in ascites fluid, following 
the initial burst release of the siRNA which is complexed on the surface of the liposomes and 
exposed to the proteins in the ascites fluid. Unfortunately, the high stability of the HYDRA-
LPXs and DSPE HYDRA-LPXs was not observed for the formulations containing C8 and C16 
Cer-PEG chains. Both formulations resulted in the formation of complexes with a low 
complexation efficiency of siRNA. Also, the majority of siRNA that was complexed, is released 
19 
 
almost immediately following incubation in ascites fluid. This rapid and premature release most 
likely stems from a re-organization on the level of the lipid bilayer upon introducing the C8 and 
C16 Cer-PEG chains within the lipid bilayer, resulting in a smaller aqueous core and 
consequently lower complexation efficiency where most of the siRNA is free or attached to the 
surface of the complexes.  
 
Influence of stability on biological activity  
While extracellular stability is one of the major concerns when designing siRNA delivery 
systems, the internalization and intracellular interactions with the different organelles are key 
factors to ensure maximal biological activity. The size and the charge of the studied 
formulations (Table 1) suggest that these complexes can cross biological membranes and 
deliver the siRNA into cells (Figure 4). Also, all PEGylated formulations used in this study 
succeeded in preventing the aggregation of the liposomal formulations for at least 3 hours when 
incubated in ascites fluid (Figure 1). Therefore, each PEGylation strategy seems suitable to 
stabilize the formulations and to assure the presence of nano-sized formulations for a 
sufficiently long time to warrant cellular uptake. Following internalization, endosomal escape 
is essential to ensure delivery of siRNA in the cytoplasm and to induce efficient silencing of 
the target gene [4]. For the HYDRA-LPXs and Cer HYDRA-LPXs, substantial luciferase 
inhibition was observed when the incubation took place in Opti-MEM® (Figure 5, white bars), 
except for the DSPE HYDRA-LPXs formulation. In the case of the HYDRA-LPXs, the cationic 
charge facilitates the interaction and destabilization of the endosomes, leading to fusion and 
eventually release of the siRNA into the cytosol. The fusion is further enhanced when a 
fusogenic “helper lipid” is incorporated within the liposomal formulation, such as DOPE in this 
case. It has been shown that upon acidification of the endosomal compartment DOPE triggers 
a conformational change from the stable lamellar phase into the highly unstable inverted 
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hexagonal phase, which is thought to destabilize the endosomal membrane and release the cargo 
into the cytosol [41] . This conformational transition is not possible in the DSPE HYDRA-
LPXs [42]. This explains the relatively low transfection efficiency of this formulation when 
compared with other formulations (Figure 5).  
When PEGylation is performed with sheddable Cer-PEG instead of stable DSPE-PEG chains, 
it can be seen that both Cer-PEG HYDRA-LPXs result in high transfection efficiency. The 
transfection efficiency of the Cer-PEG formulations is highly likely ascribed to the “de-
PEGylation” that occurs upon interaction of the Cer-PEG formulations with the cell membrane 
[42], and consequently, similar interaction with the endosomes as the one described above for 
the HYDRA-LPXs is expected.  
Since the final goal of this study is to determine the biological activity of the studied 
formulations in a relevant undiluted biofluid, we tested the transfection efficiency of all the 
formulations following incubation in ascites fluid obtained from a peritoneal carcinomatosis 
patient. (Figure 5, grey bars). We are convinced that undiluted ascites fluids better resembles 
the in vivo peritoneal situation, not only in terms of stability, but also biological activity [20].  
The drop in the transfection efficiency observed upon incubation in ascites fluid can be 
discussed on two levels: 1) cellular uptake of the studied formulations and 2) intracellular 
trafficking of the DSPE HYDRA-LPXs specifically following internalization. In particular, the 
HYDRA-LPXs and Cer HYDRA-LPXs are not internalized into SKOV-3 cells following 1 h 
of incubation in ascites fluid (Figure 4). Consequently, the cargo (i.e. siRNA) is not delivered 
into the cytoplasm of the cell where it should be further processed by the RNAi machinery, 
leading eventually to the absence of biological activity depicted in Figure 5.  
Based on the stability data in Figure 1 and Figure 2, DSPE HYDRA-LPXs are protected from 
aggregation in the presence of ascites fluid and are able to keep the siRNA encapsulated for a 
sufficient long time to allow internalization into the cells. Therefore, the poor transfection 
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efficiency observed for the DSPE HYDRA-LPXs is mainly due to the poor interaction with the 
endosomes, as also observed for the transfections in Opti-MEM®. The poor transfection 
efficiency of the DSPE-PEG formulation stands in line with recently published data, where 
DOTAP/cholesterol pDNA LPXs with 2% DSPE-PEG diminished the transfection compared 
to the non-PEGylated LPXs in vitro [43]. Additionally, DOTAP DOPE LPXs loaded with 
survivin siRNA and grafted with 1% DSPE-PEG successfully downregulated the activity of 
survivin in cultured cells, but lost its activity in peritoneal tumors in vivo [33].  
Taken together, the findings of this study provide an evidence of the sensitive interplay that 
exists between extracellular stability, cellular uptake and biological activity when developing 
nano-sized siRNA formulations in protein-rich biological fluids. An optimal formulation 
designated for in vivo applications should fulfill all the requirements of colloidal stability, 
interaction with biological barriers, and intracellular trafficking in the relevant biofluid. One 
should keep in mind that formulations that show good stability and transfection characteristics 
in protein-free conditions such as Opti-MEM®, do not necessarily translate in potent 
formulations when transfections are being performed in the relevant biological fluids. For the 
formulations tested in this study, cellular uptake was the bottleneck for obtaining efficient gene 
knockdown, whereas poor intracellular processing was most probably the reason for the low 
gene knockdown observed with the only formulation taken up by the cells following incubation 
in undiluted ascites fluid (i.e. DSPE HYDRA-LPX).The cellular uptake in this case was not a 
problem, since this formulation exhibited low transfection efficiency (Figure 5) even in protein-
free conditions (i.e. Opti-MEM®), where efficient internalization occurred.  
 
Conclusions  
In this study we tested the stability of different liposomal formulations for i.p. siRNA delivery 
based on the hydration technique and different types of PEGylation in human undiluted ascites 
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fluid, as well as, the transfection efficiency in the SKOV-3 ovarian cancer cell line. We 
hypothesized that liposomes encapsulating siRNA and grafted with Cer-PEG chains would be 
an ideal platform for i.p. siRNA delivery. Nonetheless, our findings revealed that these carriers 
are not taken up by SKOV-3 cells in protein-rich conditions (i.e. ascites fluid). On the contrary, 
liposomes encapsulating siRNA and coated with stable DSPE-PEG are endocytosed by SKOV-
3 cells in protein-rich conditions, but are associated with poor biological activity highly likely 
due to insufficient intracellular processing.   
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